A Phase 1 interventional study of VX-581 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 22nd largest by planned enrollment, is one of 2 that started in 2025, is one of 12 in phase 1, and was the 82nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 152 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 36th largest by planned enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2025, is one of 28 in phase 1, and was the 122nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
The study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581 in healthy participants and in participants with CF. VX-581 will be administered alone and in combination with TEZ and D-IVA. The study consists of Screening Phase, Run-In Phase (CF only), Treatment Phase and Safety Follow-up Phase.
Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
The criteria were revised on the registry on Oct 19, 2026. See what changed
Key Inclusion Criteria:
Parts A, B, C:
Part D:
Key Exclusion Criteria:
Parts A, B, C:
Part D:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive a single dose of VX-581.
Drug: VX-581
Participants will be randomized to receive a single dose of placebo matched to VX-581.
Drug: Placebo
Participants will be randomized to receive multiple doses of VX-581.
Drug: VX-581
Participants will be randomized to receive multiple doses of placebo matched to VX-581.
Drug: Placebo
Participants will be randomized to receive multiple doses VX-581 in combination with TEZ/D-IVA or D-IVA.
Drug: VX-581 · Drug: D-IVA · Drug: TEZ
Participants will be randomized to receive placebo matched to VX-581 in combination with TEZ/D-IVA or D-IVA.
Drug: Placebo · Drug: D-IVA · Drug: TEZ
Participants with CF will enter a run-in period and receive ELX/TEZ/IVA. Following the run-in period participants will receive VX-581 in combination with TEZ/D-IVA or D-IVA in the treatment period. Following the treatment period, participants will enter a 14-day Washout Period and receive ELX/TEZ/IVA. (Part D will be open-label)
Drug: D-IVA · Drug: TEZ · Drug: ELX/TEZ/IVA · Drug: VX-581 · Drug: IVA
Suspension for Oral Administration.
Suspension for Oral Administration.
Tablet for Oral Administration.
Also known as: deutivacaftor, VX-561
Tablet for Oral Administration.
Also known as: tezacaftor, VX-661
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed dose combination (FDC) Tablets for Oral Administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablets for Oral Administration.
Tablet for Oral Administration.
Also known as: VX-770, Ivacaftor
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day -1 up to Day 8
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day -1 up to Day 17
Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day -1 up to Day 17
Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Signing of Informed Consent up to Day 105
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-581
Time frame: On Day 1
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Up to 24 Hours (AUC0-24h) Post-Dose of VX-581
Time frame: On Day 1
Part B: Cmax of VX-581
Time frame: On Days 1, 7, and 10
Part B: AUC0-24h Post-Dose of VX-581
Time frame: On Days 1, 7, and 10
Part C: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time frame: On Days 1, 7, and 10
Part C: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time frame: On Days 1, 7, and 10
Part D: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time frame: On Day 1 and Day 28
Part D: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time frame: On Day 1 and Day 28
Part D: Absolute Change in Sweat Chloride (SwCl)
Time frame: From Baseline Up To Day 28
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.
Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 19 months is above that.
Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Nov 2026 → Jul 2027 and completion Nov 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ivacaftor · Tezacaftor
Vertex Pharmaceuticals Incorporated →